KALA focused on the development and commercialization of therapeutics using proprietary AMPPLIFY mucus-penetrating particle, or MPP, drug delivery technology, with an initial focus on the treatment of eye diseases
INVELTYS - approved by FDA on August 22, 2018. US launch in January 2019
KPI121 0.25% - on PH3 (Third trail on-going), Top line results expected in Q4 2019
Cash - 170M$ (31.12.2018)
2018 Net Loss - 66M$
MKT Cap - 286M$
INVELTYS - approved by FDA on August 22, 2018. US launch in January 2019
KPI121 0.25% - on PH3 (Third trail on-going), Top line results expected in Q4 2019
Cash - 170M$ (31.12.2018)
2018 Net Loss - 66M$
MKT Cap - 286M$